Central Provident Fund (Medisave Account Withdrawals) (Amendment No. 3) Regulations 2022

Status:

Published in Subsidiary Legislation Supplement
on 31 Aug 2022

No. S 716

Central Provident Fund Act 1953

Central Provident Fund
(Medisave Account Withdrawals)
(Amendment No. 3) Regulations 2022

In exercise of the powers conferred by section 77(1)(j) of the Central Provident Fund Act 1953, the Minister for Manpower, after consulting with the Central Provident Fund Board, makes the following Regulations:

Citation and commencement

1. These Regulations are the Central Provident Fund (Medisave Account Withdrawals) (Amendment No. 3) Regulations 2022 and come into operation on 1 September 2022.

Amendment of regulation 2

2. In regulation 2(1) of the Central Provident Fund (Medisave Account Withdrawals) Regulations (Rg 17) (called in these Regulations the principal Regulations) —

(a)

after the definition of “approved allied health professional”, insert —

“ “approved cancer drug” means any active ingredient (or combination of active ingredients) in the dosage form and strength listed in the CDL and administered for the corresponding clinical indication listed in the CDL;”;

(b)

after the definition of “approved vaccination”, insert —

“ “cancer drug” means any drug, including any approved cancer drug, used for the treatment of neoplasms;

“cancer drug treatment” means —

(a)	the administration of any cancer drug for the treatment of neoplasms; or
(b)	any other medical treatment or services ancillary to the administration of any cancer drug for the treatment of neoplasms;

“cancer scan or diagnostic test” means any scan or diagnostic test (which may include magnetic resonance imaging (MRI), computerised tomography (CT) scans, positron emission tomography (PET) scans, ultrasound imaging, x‑rays, mammograms and blood tests) performed —

(a)	for the purpose of investigating any known neoplasms in a patient; or
(b)	in relation to any treatment of neoplasms received by a patient;

“CDL” means the Cancer Drug List published on the website of the Ministry of Health at https://www.moh.gov.sg;

“chemotherapy”, in relation to the treatment of neoplasms, means the administration of tested and approved chemotherapeutic agents by the usual and known routes;”;

(c)

in the definition of “medical treatment”, in paragraph (a)(i), replace “treatment of neoplasms by chemotherapy” with “cancer drug treatment”;

(d)

in the definition of “out-patient scan”, in paragraph (b)(i), delete “defined in regulation 13(7)”; and

(e)

replace the definition of “treatment of neoplasms by chemotherapy” with —

“ “treatment of neoplasms” means the treatment of malignant neoplasms, certain benign neoplasms and neoplasms of uncertain behaviour.”.

Amendment of regulation 13

3. In regulation 13 of the principal Regulations —

(a)

in paragraph (3), after “Subject to”, insert “paragraphs (6) and (7) and”;

(b)

in paragraph (6), after “undergone”, insert “, on or after 1 April 2008 but before 1 September 2022,”;

(c)

in paragraph (6), replace “that cancer scan or diagnostic test” with “item 11 of that Schedule”; and

(d)

replace paragraph (7) with —

“(7) Subject to regulations 21C and 21D, where a member or a member’s dependant has undergone, on or after 1 September 2022 —

(a)	any cancer scan or diagnostic test, ordered by an approved medical practitioner, as an out‑patient in an approved medical institution; or
(b)	any cancer drug treatment as an out‑patient from an approved medical practitioner in an approved hospital, approved centre or approved clinic,

the amount that may be withdrawn by the member for the payment of such cancer drug treatment, cancer scan or diagnostic test must not exceed the sum specified in the third column of the First Schedule in relation to item 12 or 13 or both, as the case may be.”.

Amendment of regulation 21C

4. In regulation 21C(1)(a) of the principal Regulations, replace sub‑paragraphs (ii), (iii) and (iv) with —

“(ii)	any First Schedule treatment (other than a cancer scan or diagnostic test) provided by an approved medical practitioner in an approved hospital, approved centre or approved clinic;
(iii)	any cancer scan or diagnostic test ordered by an approved medical practitioner and provided in an approved medical institution;
(iv)	any Third Schedule treatment provided by an approved medical practitioner in an approved Third Schedule treatment provider;”.

Amendment of regulation 24

5. In regulation 24 of the principal Regulations —

(a)

in paragraph (1), replace sub-paragraph (e) with —

“(e)	any First Schedule treatment (other than a cancer scan or diagnostic test) provided on an out-patient basis at subsidised rates by an approved medical practitioner in an approved hospital, approved centre or approved clinic;
(ea)	any cancer scan or diagnostic test ordered by an approved medical practitioner and provided on an out‑patient basis at subsidised rates in an approved medical institution;
(eb)	any Third Schedule treatment provided on an out‑patient basis at subsidised rates by an approved medical practitioner in an approved Third Schedule treatment provider;”;

(b)

in paragraph (1A)(b), replace “or (e)” with “, (e), (ea) or (eb)”; and

(c)

delete paragraph (3).

Amendment of First Schedule

6. In the First Schedule to the principal Regulations —

(a)

in item 3, in the second column, after “1 November 2015”, insert “but before 1 September 2022”;

(b)

in item 11, in the second column, replace “1st April 2008” with “1 April 2008 but before 1 September 2022”; and

(c)

after item 11, insert —

“12.	Cancer drug treatment (excluding the cost of any cancer drug administered), cancer scan or diagnostic test

With effect from 1 September 2022

$600 per year per patient or the total credit balance in the member’s medisave account, whichever is the lower.

13.	Approved cancer drug administered for the treatment of neoplasms:

(a)	where only approved cancer drugs listed in the first tier of the CDL are administered in a month

With effect from 1 September 2022

$600 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.

(b)	where only approved cancer drugs listed in the second tier of the CDL are administered in a month

With effect from 1 September 2022

$1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.

(c)	where approved cancer drugs listed in both the first tier and the second tier of the CDL are administered in a month

With effect from 1 September 2022

$1,200 per month per patient or the total credit balance in the member’s medisave account, whichever is the lower.”.

Amendment of Second Schedule

7. In the Second Schedule to the principal Regulations, in item 1, after “clinical trial”, insert “but excluding any cancer drug treatment”.

[G.N. Nos. S 224/2007; S 527/2007; S 731/2007; S 149/2008; S 456/2008; S 682/2008; S 86/2009; S 239/2009; S 523/2009; S 659/2009; S 88/2010; S 118/2010; S 289/2010; S 548/2010; S 367/2011; S 725/2011; S 107/2013; S 482/2013; S 623/2013; S 427/2014; S 872/2014; S 177/2015; S 625/2015; S 377/2016; S 530/2016; S 723/2016; S 340/2017; S 789/2017; S 145/2018; S 341/2018; S 730/2018; S 787/2018; S 397/2019; S 200/2020; S 389/2020; S 855/2020; S 899/2020; S 1089/2020; S 131/2021; S 157/2021; S 315/2021; S 3/2022; S 285/2022]

Made on 29 August 2022.

NG CHEE KHERN

Permanent Secretary,
Ministry of Manpower,
Singapore.

[Plg&Pol/CPFPol/Legis/CPFSL/2022; AG/LEGIS/SL/36/2020/3 Vol. 5]

(To be presented to Parliament under section 78(2) of the Central Provident Fund Act 1953).

Search within Legislation